Lupus Research Alliance Honors the Life of its Former Leader Margaret G. Dowd
The Lupus Research Alliance mourns the death of Margaret “Peggy” G. Dowd, its former Co-President and Co-CEO and relentless...
FDA Accepts Application for Gazyva® as Potential Lupus Nephritis Treatment
FDA Accepts Application for Gazyva® as Potential Lupus Nephritis Treatment
Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, is eager to share exciting news. The U.S. Food and Drug Administration accepted the supplemental Biologics License Application (sBLA) from Genentech for Gazyva® (obinutuzumab) as a potential treatment of lupus nephritis. This development provides hope for another treatment option for those living with lupus nephritis.
